Skip to main content
. 2014 May-Jun;89(3):436–440. doi: 10.1590/abd1806-4841.20142613

TABLE 4.

Distribution of anti-TNFα treatment according to frequency and duration of treatment (as mean ± standard deviation) in months

  Frequency
Anti-TNFα agent used      
  Infliximab   48.6% (36)  
  Etanercept   32.4% (24)  
  Adalimumab   18.9% (14)  
Duration of treatment (months)      
  Mean   22.06±15.7  
  Range   3-72